Susquehanna International Group, LLP Pharma Cyte Biotech, Inc. Transaction History
Susquehanna International Group, LLP
- $568 Billion
- Q1 2025
A detailed history of Susquehanna International Group, LLP transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 18,406 shares of PMCB stock, worth $19,510. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,406
Previous 34,481
46.62%
Holding current value
$19,510
Previous $53,000
56.6%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PMCB
# of Institutions
29Shares Held
674KCall Options Held
13.7KPut Options Held
2.1K-
Vanguard Group Inc Valley Forge, PA195KShares$206,1890.0% of portfolio
-
Geode Capital Management, LLC Boston, MA139KShares$147,2710.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$97,6127.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$87,6900.08% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny49.5KShares$52,4700.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $22M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...